Answers are grounded in this paper and cite their sources.
Background: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). Methods: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m 2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m 2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). Results: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m 2 , and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m 2 /year (95% CI, 0.5–2.2; P =0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m 2 /year), and among participants with primary or secondary FSGS ( P -interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30–1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%–53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0–17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. Conclusions: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: